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Abstract
Our laboratory has developed phage lytic enzymes to prevent infection by specifically destroying
disease bacteria on mucous membranes and in blood. Enzymes specific for S. pneumoniae and S.
pyogenes  have been developed to be used nasally and orally to control these organisms in
environments such as hospitals and nursing homes to prevent or markedly reduce serious
infections by these pathogens. In addition, a B. anthracis-specific enzyme was developed to kill the
vegetative forms of these bacteria in the blood of infected individuals. In animal studies, >80% of
mice colonized mucosally or infected intravenously with pathogenic bacteria were decolonized or
survived after a single enzyme treatment delivered to the same site of colonization or infection.
Introduction
Bacteriophages infect their host bacteria to produce more
virus particles. At the end of the reproductive cycle (which
may last up to an hour) they are faced with a problem,
how to release the progeny phage trapped within the bac-
terium [1]. They solve this problem by producing an
enzyme called lysin that degrades the cell wall of the
infected bacteria to release the progeny phage. The lytic
system consists of a holin [1] and at least one peptidogly-
can hydrolase, or lysin, capable of degrading the bacterial
cell wall. Lysins can be endo-beta-N-acetyl-glucosamini-
dases or N-acetylmuramidases (lysozymes), which act on
the sugar moiety, endopeptidases, which act on the pep-
tide cross bridge, or more commonly, an N-acetyl-
muramoyl-L-alanine amidase (or amidase), which
hydrolyzes the amide bond connecting the sugar and pep-
tide moieties. Typically, the holin is expressed in the late
stages of phage infection, forming a pore in the cell mem-
brane, allowing the preformed lysin(s) to gain access to
the cell wall peptidoglycan, resulting in release of progeny
phage. Significantly, exogenously added lysin can lyse the
cell wall of healthy, uninfected cells, producing a phe-
nomenon known as lysis from without. However, because
of the lack of an outer membrane, this event is observed
only in gram-positive bacteria.
While lysins have been known for many years [2-5], our
laboratory is the first to use these enzymes therapeutically
and prophylactically in vivo in their purified form to kill
colonizing pathogenic bacteria on mucous membrane
surfaces and in blood. We have been successful in using
such enzymes to kill S. pyogenes [6,7] and more recently,
B. anthracis [8]. All of these enzymes are highly evolved
molecules designed for a specific purpose, to quickly
destroy the bacterial cell wall, and as such, we find that
nanogram to sub-microgram quantities of enzyme per
milliliter is sufficient to sterilize a 107 bacterial suspension
in seconds. To date, other than chemical agents, there is
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no biological compound known that can kill bacteria this
quickly. Such phage lytic enzymes are the culmination of
millions of years of development by the bacteriophage
and its association with bacteria. Since nearly all bacteria
are or can be infected by bacteriophage, such enzymes
may be developed for nearly all disease-causing bacteria.
It appears, however, that these enzymes work best against
gram-positive bacteria. In these organisms, the enzyme is
able to rapidly access the bonds in the peptidoglycan
when added extrinsically. In the gram-negative bacteria,
the outer membrane is a barrier for these enzymes.
Enzyme Structure
A feature of those phage lytic enzymes that have been
characterized so far is their domain structure [9,10]. Gen-
erally, the N-terminal domain contains the catalytic activ-
ity of the enzyme, which will cleave one of the four major
bonds in the peptidoglycan of the bacterial cell wall as
described above [1]. Of the phage lytic enzymes that have
been reported thus far, the great majority are amidases.
The C-terminal domain of phage lytic enzymes has specif-
icity for a cell wall substrate [11-14]. Thus, unless the
binding domain binds to its wall substrate, the catalytic
domain will not cleave, offering specificity to most
enzymes studied. The reason for this specificity was not
apparent at first, since it seemed counterintuitive that the
phage would specifically design an enzyme that was lethal
for its host organism. However, as we learned more about
how these enzymes function, the possible reason for this
specificity became apparent (see below, Resistance to
Enzymes).
Mode of Action
By thin section electron microscopy of phage enzyme-
treated bacteria, it appears that the enzymes exert their
lethal effects by digesting the peptidoglycan in localized
areas, forming holes in the cell wall. Because the osmotic
pressure inside a bacterium is approximately 3 atmos-
pheres in relation to the normal external environment,
this results in extrusion of the cytoplasmic membrane
and, ultimately, hypotonic lysis. Since it has been found
by Loessner [14] that these enzymes bind at an affinity of
an immunoglobulin molecule, they are essentially one-
use enzymes and require multiple molecules to accom-
plish the job of digesting the cell wall. One explanation as
to why these molecules have evolved in this way is that
after lysis the tight binding to the wall substrate will
restrict the movement of enzyme molecules, preventing
lysis of potential phage hosts nearby.
Targeted Killing
An interesting feature of these enzymes is that they kill the
species of bacteria from which they were produced. For
instance, enzymes produced from streptococcal bacteri-
ophage kill streptococci, and enzymes produced by pneu-
mococcal bacteriophage kill pneumococci  [6,7].
Specifically, the group C streptococcal lysin will kill group
A streptococci efficiently and has a small effect on groups C
and G streptococci, but has essentially no effect on normal
oral streptococci. Similar results are seen with a pneumo-
coccal-specific lysin. However in this case, the enzyme was
also tested against strains of pneumococci that were resist-
ant to penicillin, and the killing efficiency was the same.
Unlike antibiotics, which are usually broad spectrum and
kill many different bacteria found in the human body,
some of which are beneficial, the phage enzymes only kill
the disease bacteria with little to no effect on the normal
human bacterial flora. Thus, phage lysins are molecules
that enable targeted killing of pathogenic bacteria with lit-
tle effect on the surrounding normal flora. When the
group A streptococcal enzyme was tested for safety in two
animal model systems, one mucosal and the other skin, in
which enzyme was added to these surfaces daily for 7
days, and the tissues examined both visually and histolog-
ically, nothing unusual was observed. This was not sur-
prising since the bonds cleaved by the phage enzymes are
only found in bacteria and not human tissues. Thus, it is
anticipated that these enzymes will be well tolerated in
humans.
In vivo Experiments
Two in vivo animal models of mucosal colonization were
developed to test the capacity for the lysins to kill organ-
isms on these surfaces. An oral colonization model was
developed for group A streptococci, and a nasal model was
developed for pneumococci [6,7]. In both cases, when the
animals were colonized with their respective bacteria and
treated with a small amount of lysin specific for the colo-
nizing organism, the animals were found to be free of col-
onizing bacteria two to five hours after lysin treatment. In
the group A streptococcal experiment, animals were also
swabbed 24 and 48 hours after lysin treatment. During
that time most animals remained negative for streptococci,
but one animal had died and two others showed positive
colonies. We interpret these results to mean that the posi-
tive animals became infected during the first four days of
colonization, where some organisms became intracellu-
lar. Thus, while the lysin is able to clear organisms found
on the surface, it was unable to kill organisms that had ini-
tiated an infection. We ruled out the possibility that the
organisms that appeared at 24 and 48 hrs did so because
they became resistant to the lysin by checking them for
their sensitivity to the lysin.
Controling Anthrax
Because phage enzymes are so efficient in killing patho-
genic bacteria, they may be valuable tools in controlling
biowarfare bacteria. To determine the feasibility of the
approach, we identified a lytic enzyme from the gamma
phage that is specific for Bacillus anthracis [15]. In cloningBMC Oral Health 2006, 6:S16
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experiments using the gamma-phage DNA, we identified
a ~700 bp ORF in the phage genome encoding a 26 kDa
product very similar in size and features to a variety of
Bacillus  and  Listeria, phage lysins. The gamma lysin,
referred to as PlyG, was then purified to homogeneity by
a two-step ion exchange chromatography procedure and
tested for its lethal action on gamma phage sensitive
bacilli. Three seconds after contact, as little as 10 ug of
PlyG mediated a 5,000-fold decrease in viable counts of a
~107 bacillus culture [8]. This lethal activity was observed
in growth media, phosphate buffer, and even human
blood. When the enzyme was then tested against five
mutant B. anthracis strains and ten different virulent B.
anthracis strains isolated worldwide, it was found to be
lethal for them all. Although PlyG has no effect on B.
anthracis spores, we discovered that the addition of the
germinant L-alanine after a short heat shock of 60C
resulted in the rapid germination of the spore, at which
time the enzyme was rapidly lethal.
When 107 Bacillus cereus strain RSVF (a close relative to B.
anthracis) were administered intraperitoneally (IP) to fif-
teen mice, all died of rapidly fatal septicemia within four
hours. When two sets of mice (n = 8 and n = 17) were also
challenged IP with bacilli but given 150 µg and 50 µg of
PlyG respectively 15 minutes later by the same route,
70%–80% of the animals survived. We anticipate that
higher doses of enzyme or multiple doses will result in
nearly 100% protection. In a separate experiment, two
groups of mice were given 124 cfu of the B. anthracis Ames
strain intravenously, and 15 minutes later one group
received PlyG and the other buffer by the same route.
When followed for 12 days, 90% of the enzyme treated
mice survived, while only 10% of the control animals sur-
vived. Thus, we anticipate that this approach may be used
in post-exposure cases of anthrax, in which individuals
will be treated intravenously with PlyG to control the
bacilli entering the blood after germination. This strategy
could perhaps extend the window of antibiotic therapy
and allow the innate immune system to clear any remain-
ing bacilli.
Resistance to Enzymes
Repeated exposure to low concentrations of lysin to bac-
teria grown on agar plates did not lead to the recovery of
resistant strains, nor were we able to identify resistant bac-
teria after several cycles of exposure to low concentrations
of enzyme in liquid [7]. This may be explained by the fact
that the cell wall receptor for the pneumococcal lysin is
choline [16], a molecule that is necessary for pneumococ-
cal viability. For group A streptococci, we find that polyr-
hamnose, a cell wall component of the bacteria, is
necessary for lysin binding (Nelson and Fischetti, unpub-
lished), and polyrhamnose has also been shown to be
important for streptococcal growth. While not yet proven,
it is possible that during a phage's association with bacte-
ria over the millennia, to avoid becoming trapped inside
the host cell, the binding domain of their lytic enzymes
has evolved to target a unique and essential molecule in
the cell wall, making resistance to these enzymes a rare
event.
Immune Response to Enzymes
Because enzymes are proteins, one would anticipate an
immune response to these molecules when delivered
mucosally or systemically, resulting in the neutralization
of the enzymatic activity. In order to test this, rabbits were
hyperimmunized to the PlyG enzyme and the resulting
antibodies tested in an ELISA assay. We found that in the
two rabbits immunized, an antibody titer of >25,000
(reciprocal of the highest serum dilution yielding an OD
of 1.0 in 30 min) was found for both antisera. When PlyG
was diluted 1:1 with undiluted (or diluted) antisera or
preimmune serum and tested for its lytic activity, no dif-
ference was observed in the lytic activity in the immune or
preimmune sera. Thus, antibodies do not have the capac-
ity to inactivate the PlyG, indicating that it may be used
chronically or for extended periods. This does not appear
to be a feature of the PlyG lysin alone, since similar results
were observed with antibodies to the Cpl-1 enzyme
directed to pneumococci [17].
Conclusion
Phage enzymes have a broad application. Whenever there
is a need to kill bacteria, and contact can be made with the
organism, phage enzymes may be freely utilized. They
may be used not only to control pathogenic bacteria on
human mucous membranes, but may find utility in the
food industry to control disease bacteria. Because of the
serious problems of resistant bacteria in hospitals, day
care centers, and nursing homes, particularly staphylococci
and pneumococci, such enzymes may be of immediate ben-
efit in these environments. Thus, we may add phage
enzymes to our armamentarium against pathogenic bac-
teria. They are molecules that have been in development
for millions of years by bacteriophage in their battle to
survive within bacteria. They have yet to be exploited.
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